Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial

OBJECTIVES: To investigate efficacy and safety of the Janus kinase-1 inhibitor filgotinib in patients with active rheumatoid arthritis (RA) with limited or no prior methotrexate (MTX) exposure. METHODS: This 52-week, phase 3, multicentre, double-blind clinical trial (NCT02886728) evaluated once-dail...

Descripción completa

Detalles Bibliográficos
Autores principales: Westhovens, René, Rigby, William F C, van der Heijde, Désirée, Ching, Daniel W T, Stohl, William, Kay, Jonathan, Chopra, Arvind, Bartok, Beatrix, Matzkies, Franziska, Yin, Zhaoyu, Guo, Ying, Tasset, Chantal, Sundy, John S, Jahreis, Angelika, Mozaffarian, Neelufar, Messina, Osvaldo Daniel, Landewé, Robert BM, Atsumi, Tatsuya, Burmester, Gerd R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142453/
https://www.ncbi.nlm.nih.gov/pubmed/33452004
http://dx.doi.org/10.1136/annrheumdis-2020-219213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142453/
https://www.ncbi.nlm.nih.gov/pubmed/33452004
http://dx.doi.org/10.1136/annrheumdis-2020-219213

Ejemplares similares